Fennec Pharmaceuticals Stock News

NEW YORK, Feb. 14, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. ("Fennec" or the "Company") (NASDAQ: FENC) and certain of its officers. The class action, filed in the United States District Court for the Middle…

Fennec Pharmaceuticals Inc. (FENC) Failed to Remediate Issues with the Manufacturing Facility for PEDMARK

NEW YORK, Feb. 13, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Biogen, Inc. (NASDAQ: BIIB ), Telos Corporation (NASDAQ: TLS ), Fennec Pharmaceuticals, Inc. (NASDAQ: FENC ), and Astra Space, Inc. (NASDAQ: ASTR ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Biogen, Inc. (NASDAQ: BIIB ) Class Period: June 7, 2021 January 11, 2022 Lead Plaintiff Deadline: April 8, 2022 The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab''s effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding aducanumab''s effectiveness; (3) the PRIME study did not and would not provide necessary data regarding aducanumab''s effectiveness; (4) the data provided by the Company to the FDA''s Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, defendants'' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

ROSEN, A LEADING LAW FIRM, Encourages Fennec Pharmaceuticals Inc. Investors With Losses to Secure Counsel Before Important Deadline in Secur

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC) investors concerning the Company’s possible violations of the federal securities laws. If you suffered a loss on your Fennec investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securi

NEW YORK, Feb. 11, 2022 /PRNewswire/ -- Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Fennec Pharmaceuticals Inc. ("Fennec" or the "Company") (NASDAQ: FENC) between May 28, 2021 and…

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC) investors concerning the Company’s possible violations of federal securities laws. On November 29, 2021, before the market opened, Fennec issued a press release announcing that it expects to receive a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its resubmitted PEDMARK New Dr

NEW YORK, Feb. 11, 2022 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. ("Fennec" or the "Company") (NASDAQ: FENC) and certain of its officers, on behalf of…

Fennec Pharmaceuticals Inc. (FENC) Failed to Remediate Issues with the Manufacturing Facility for PEDMARK

NEW YORK, Feb. 10, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between May 28, 2021 and November 26, 2021, inclusive (the…

RESEARCH TRIANGLE PARK, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a u

Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) have been assigned an average rating of Buy from the six ratings firms that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month target price among []

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) concluded the trading at $4.43 on Friday, December 03 with a rise of 4.24% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $4.25 and 5Y monthly beta was reading 0.09 with its price kept floating in the Fresh Data-Based Insight On Fennec Pharmaceuticals Inc. (FENC) Read More »

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify.

On November 30th, Fennec Pharmaceuticals ($FENC) received a Complete Response Letter (CRL) - a rejection document - from the FDA for its Continue reading on Medium »